{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:47:22Z","timestamp":1770486442760,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Ped Infect Dis"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1093\/jpids\/piv064","type":"journal-article","created":{"date-parts":[[2016,1,24]],"date-time":"2016-01-24T01:28:17Z","timestamp":1453598897000},"page":"180-187","source":"Crossref","is-referenced-by-count":38,"title":["Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents"],"prefix":"10.1093","volume":"5","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,1,23]]},"reference":[{"key":"2016051909224982000_5.2.180.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"2016051909224982000_5.2.180.2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1314"},{"key":"2016051909224982000_5.2.180.3","unstructured":"European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2006. Available at: http:\/\/www.hpa-bioinformatics.org.uk\/euibis\/documents\/2006_meningo.pdf. Accessed April 30, 2014."},{"key":"2016051909224982000_5.2.180.4","unstructured":"Public Health England. Invasive meningococcal infections laboratory reports, England and Wales by capsular group & epidemiological year, 1998\/99\u20132012\/13* (*provisional). Available at: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/401058\/Table_1_Invasive_meningococcal_infections_lab_reports__E_W_by_capsular_group___epi_year.pdf. Accessed June 9, 2014."},{"key":"2016051909224982000_5.2.180.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071943"},{"key":"2016051909224982000_5.2.180.6","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008\/09. Available at: http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/1107_SUR_IBD_2008-09.pdf. Accessed June 9, 2014."},{"key":"2016051909224982000_5.2.180.7","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). Available at: http:\/\/www.cdc.gov\/abcs\/reports-findings\/surv-reports.html. Accessed August 4, 2014."},{"key":"2016051909224982000_5.2.180.8","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"2016051909224982000_5.2.180.9","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31829aa63b"},{"key":"2016051909224982000_5.2.180.10","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"2016051909224982000_5.2.180.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70087-7"},{"key":"2016051909224982000_5.2.180.12","doi-asserted-by":"publisher","DOI":"10.1086\/600141"},{"key":"2016051909224982000_5.2.180.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.075"},{"key":"2016051909224982000_5.2.180.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.092"},{"key":"2016051909224982000_5.2.180.15","unstructured":"US Food and Drug Administration. First vaccine approved by FDA to prevent serogroup B meningococcal disease. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm420998.htm. Accessed October 29, 2014."},{"key":"2016051909224982000_5.2.180.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.083"},{"key":"2016051909224982000_5.2.180.17","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34293"},{"key":"2016051909224982000_5.2.180.18","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Broder","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2016051909224982000_5.2.180.19","unstructured":"Sanofi Pasteur MSD. Repevax patient information leaflet. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/17377\/PIL\/repevax\/. Accessed March 31, 2014."},{"key":"2016051909224982000_5.2.180.20","unstructured":"Electronic Medicines Compendium. Repevax: summary of product characteristics. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/15256. Accessed June 16, 2014."},{"key":"2016051909224982000_5.2.180.21","unstructured":"World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A\/C vaccines. Geneva, March 8\u20139, 1999. Available at: https:\/\/extranet.who.int\/iris\/restricted\/handle\/10665\/66298. Accessed October 8, 2014."},{"key":"2016051909224982000_5.2.180.22","first-page":"289","article-title":"Serogroup B and C serum bactericidal assays","volume":"66","author":"Borrow","year":"2001","journal-title":"Methods Mol Med"},{"key":"2016051909224982000_5.2.180.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.05.034"},{"key":"2016051909224982000_5.2.180.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.1999.01202.x"},{"key":"2016051909224982000_5.2.180.25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"2016051909224982000_5.2.180.26","unstructured":"US Food and Drug Administration. Use of serum bactericidal antibody as an immunological correlate for demonstrating effectiveness of meningococcal conjugate vaccines (serogroups A, C, Y, W-135) adminstered to children less than 2 years of age. Available at: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/bloodvaccinesandotherbiologics\/vaccinesandrelatedbiologicalproductsadvisorycommittee\/ucm248585.pdf. Accessed June 16, 2014."},{"key":"2016051909224982000_5.2.180.27","first-page":"1","article-title":"General recommendations on immunization\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"National Center for Immunization and Respiratory Diseases","year":"2011","journal-title":"MMWR Recomm Rep"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/5\/2\/180\/17488004\/piv064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T02:25:36Z","timestamp":1503627936000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article-lookup\/doi\/10.1093\/jpids\/piv064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,23]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,5,19]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1093\/jpids\/piv064"],"URL":"https:\/\/doi.org\/10.1093\/jpids\/piv064","relation":{},"ISSN":["2048-7193","2048-7207"],"issn-type":[{"value":"2048-7193","type":"print"},{"value":"2048-7207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,23]]}}}